Exploring Novel Oxazole Derivatives for Cancer Therapy: Design, Synthesis, and Mechanistic Insights.

Mushtaque A S Shaikh, Pawan Jadhav, Trupti Jadhav, Bhagyashree Jain, Ankit Jogi, Manjusha Sanap, Sunayana Ghodgaonkar
{"title":"Exploring Novel Oxazole Derivatives for Cancer Therapy: Design, Synthesis, and Mechanistic Insights.","authors":"Mushtaque A S Shaikh, Pawan Jadhav, Trupti Jadhav, Bhagyashree Jain, Ankit Jogi, Manjusha Sanap, Sunayana Ghodgaonkar","doi":"10.2174/0115701638370100250527073704","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The search for potent anticancer agents has accelerated the evaluation of a wide variety of pharmacological scaffolds, including oxazole derivatives. Although they are currently underexplored, they are promising as anticancer agents. This research covers the synthesis and structure-activity relationships of oxazole-based compounds.</p><p><strong>Methods: </strong>The authors designed and synthesized new oxazole derivatives and screened them for their anticancer activity using both computational and experimental methods. Molecular docking studies were performed to identify possible targets based on literature and the interaction of these molecules with anticancer targets like c-Kit tyrosine kinase (TRK) and MDM2. The compounds were tested using the MTT assay on a panel of different cancer cell lines, including MCF-7, to evaluate their potential effectiveness.</p><p><strong>Results: </strong>Optimized and robust synthetic procedures were developed for oxazole-based Schiff bases, with their structures confirmed through spectral analyses. Compounds 4a-e exhibited significantly stronger anticancer activity, suggesting some Structure-Activity Relationship (SAR) nuances within the series. The biological activities (IC₅₀) were determined to be in the range of 80-100 μg/mL, while molecular docking indicated that compound 4c could serve as a potential lead for c-Kit Tyrosine Kinase (TRK) inhibition.</p><p><strong>Conclusion: </strong>The results obtained from the present study corroborate the hypothesis that oxazole derivatives are potent anticancer agents, consistent with predictions from molecular docking studies. These findings highlight the significance of the oxazole scaffold in anticancer drug discovery and encourage further exploration of structure-activity relationships to enhance therapeutic potential. Although compound 4c showed better interactions in docking studies compared to biological screening, this suggests that pharmacokinetic issues should be addressed. Future studies are likely to include in vivo models and detailed mechanistic evaluations to validate these findings and support the development of oxazole-derived anticancer compounds.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug discovery technologies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115701638370100250527073704","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The search for potent anticancer agents has accelerated the evaluation of a wide variety of pharmacological scaffolds, including oxazole derivatives. Although they are currently underexplored, they are promising as anticancer agents. This research covers the synthesis and structure-activity relationships of oxazole-based compounds.

Methods: The authors designed and synthesized new oxazole derivatives and screened them for their anticancer activity using both computational and experimental methods. Molecular docking studies were performed to identify possible targets based on literature and the interaction of these molecules with anticancer targets like c-Kit tyrosine kinase (TRK) and MDM2. The compounds were tested using the MTT assay on a panel of different cancer cell lines, including MCF-7, to evaluate their potential effectiveness.

Results: Optimized and robust synthetic procedures were developed for oxazole-based Schiff bases, with their structures confirmed through spectral analyses. Compounds 4a-e exhibited significantly stronger anticancer activity, suggesting some Structure-Activity Relationship (SAR) nuances within the series. The biological activities (IC₅₀) were determined to be in the range of 80-100 μg/mL, while molecular docking indicated that compound 4c could serve as a potential lead for c-Kit Tyrosine Kinase (TRK) inhibition.

Conclusion: The results obtained from the present study corroborate the hypothesis that oxazole derivatives are potent anticancer agents, consistent with predictions from molecular docking studies. These findings highlight the significance of the oxazole scaffold in anticancer drug discovery and encourage further exploration of structure-activity relationships to enhance therapeutic potential. Although compound 4c showed better interactions in docking studies compared to biological screening, this suggests that pharmacokinetic issues should be addressed. Future studies are likely to include in vivo models and detailed mechanistic evaluations to validate these findings and support the development of oxazole-derived anticancer compounds.

探索用于癌症治疗的新型恶唑衍生物:设计、合成和机制见解。
背景:对强效抗癌药物的研究加速了各种药物支架的评估,包括恶唑衍生物。虽然它们目前尚未被充分开发,但它们作为抗癌剂是有希望的。本文研究了恶唑类化合物的合成及其构效关系。方法:设计合成新的恶唑衍生物,并采用计算和实验相结合的方法对其抗癌活性进行筛选。通过分子对接研究,根据文献以及这些分子与c-Kit酪氨酸激酶(TRK)和MDM2等抗癌靶点的相互作用,确定可能的靶点。这些化合物使用MTT试验在一组不同的癌细胞系(包括MCF-7)上进行测试,以评估它们的潜在效力。结果:优化了恶唑基席夫碱的合成工艺,并通过光谱分析确定了其结构。化合物4a-e表现出明显较强的抗癌活性,表明该系列中存在一些结构-活性关系(SAR)的细微差别。生物活性(IC₅0)被确定在80-100 μg/mL范围内,而分子对接表明化合物4c可以作为c-Kit酪氨酸激酶(TRK)抑制的潜在先导物。结论:本研究的结果证实了恶唑衍生物是强效抗癌剂的假设,与分子对接研究的预测一致。这些发现强调了恶唑支架在抗癌药物发现中的重要性,并鼓励进一步探索结构-活性关系以提高治疗潜力。虽然与生物筛选相比,化合物4c在对接研究中表现出更好的相互作用,但这表明需要解决药代动力学问题。未来的研究可能包括体内模型和详细的机制评估,以验证这些发现,并支持恶唑衍生抗癌化合物的开发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信